1-ethyl-2-hydroxy-5,6,7,8-tetrahydronaphthalene | 60401-38-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 1-ethyl-2-hydroxy-5,6,7,8-tetrahydronaphthalene
• 英文别名: 5-ethyl-6-hydroxy-1,2,3,4-tetrahydronaphthalene；1-ethyl-5,6,7,8-tetrahydronaphthalen-2-ol
• CAS: 60401-38-9
• 化学式: C₁₂H₁₆O
• 分子量: 176.258
• InChiKey: HIOGQCOVPOXABP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-cyclohexyl-1-hexen-4-yn-3-one 在 sodium tetrahydroborate 、 对甲苯磺酸 作用下， 以 甲醇 为溶剂， 反应 31.25h， 生成 1-ethyl-2-hydroxy-5,6,7,8-tetrahydronaphthalene
  参考文献：
  名称：

  Enynones in Organic Synthesis. 8. Synthesis of the Antimicrobial-Cytotoxic Agent Juncusol and Members of the Effusol Class of Phenols

  摘要：

  Two new syntheses of phenols have been developed which have been utilized in an efficient preparation of the antimicrobial-cytotoxic agent juncusol (22) and several members of the effusol (23) class of phenols. These results complement our earlier studies with enynones of type 42 and provide for the highly efficient conversion of 42 to either methylenecyclopentenones 45 or phenols of type 47 or 54 with virtually 100% selectivity.

  DOI：

  10.1021/jo00107a017

文献信息

• Tricyclic mono-chromone-2-carboxylic acids
  申请人：Fisons Limited

  公开号：US04159273A1

  公开（公告）日：1979-06-26

  There are described compounds of formula I, ##STR1## in which R.sub.3 represents hydrogen, or alkyl C 1 to 6, R.sub.5 represents hydrogen, hydroxy, alkoxy C 1 to 6, alkanoyloxy C 2 to 6, alkenyloxy C 2 to 6, nitro, -NR.sub.1 R.sub.2, halogen, alkyl C 1 to 6, hydroxy-alkyl C 1 to 6, or hydroxy-alkoxy C 1 to 6, An adjacent pair of X, Y and Z form a --(CH.sub.2).sub.4 --, --CH.dbd.CH--CH.dbd.CH--or --O(CH.sub.2).sub.3 --chain, each of the chains optionally being substituted by one or two C 1 to 6 alkyl groups, and the remaining substituent X or Z represents alkenyl C2 to 6 optionally substituted by phenyl; halogen; or alkyl C 1 to 9 optionally substituted by one or more of the groups hydroxy, halogen, carbonyl oxygen, phenyl, or alkoxy C 1 to 6, Or, when an adjacent pair of X, Y and Z form a chain substituted by one or two C 1 to 6 alkyl groups, the remaining substituent X or Z may be hydrogen, and R.sub.1 and R.sub.2, which may be the same or different, are each hydrogen or alkyl C 1 to 6, And pharmaceutically acceptable derivatives thereof. Processes for making the compounds and pharmaceutical, e.g. anti-allergic, compositions containing the compounds are also described.

  本文描述了一种化合物，其化学式为I，其中R.sub.3代表氢或烷基C1至6，R.sub.5代表氢、羟基、烷氧基C1至6、烷酰氧基C2至6、烯酰氧基C2至6、硝基、-NR.sub.1R.sub.2、卤素、烷基C1至6、羟基-烷基C1至6或羟基-烷氧基C1至6。相邻的X、Y和Z形成一个--(CH2)4--、--CH=CH-CH=CH-或--O(CH2)3--链，每个链可选地被一个或两个C1至6烷基取代，剩余的取代基X或Z代表烯基C2至6，可选地被苯基、卤素或烷基C1至9取代，该烷基可选地被一个或多个羟基、卤素、羰基氧、苯基或烷氧基C1至6的基团取代。或者，当相邻的X、Y和Z形成一个被一个或两个C1至6烷基取代的链时，剩余的取代基X或Z可以是氢，R.sub.1和R.sub.2可以相同或不同，分别代表氢或烷基C1至6。还描述了制备该化合物的方法以及含有该化合物的药物，例如抗过敏药物组成物。
• Methods and compositions for inhibition of Ras
  申请人：ARAXES PHARMA LLC

  公开号：US10011600B2

  公开（公告）日：2018-07-03

  Inhibitors of Ras protein, methods to modulate the activity of Ras protein, and methods of treatment of disorders mediated by Ras protein are provided. A method for regulating activity of a K-Ras, H-Ras or N-Ras mutant protein with a compound is described. Disorders that can be treated include cancer, such as hematological cancer, pancreatic cancer, MYH associated polyposis, colorectal cancer, or lung cancer.

  提供了 Ras 蛋白的抑制剂、调节 Ras 蛋白活性的方法以及治疗由 Ras 蛋白介导的疾病的方法。描述了一种用化合物调节 K-Ras、H-Ras 或 N-Ras 突变蛋白活性的方法。可治疗的疾病包括癌症，如血癌、胰腺癌、MYH 相关性息肉病、结直肠癌或肺癌。
• Enynones in organic synthesis. III. A novel synthesis of phenols
  作者：Peter A. Jacobi、Joseph I. Kravitz

  DOI：10.1016/s0040-4039(00)88463-4

  日期：1988.1
• METHODS AND COMPOSITIONS FOR INHIBITION OF RAS
  申请人：ARAXES PHARMA LLC

  公开号：US20170247376A1

  公开（公告）日：2017-08-31

  Inhibitors of Ras protein, methods to modulate the activity of Ras protein, and methods of treatment of disorders mediated by Ras protein are provided. A method for regulating activity of a K-Ras, H-Ras or N-Ras mutant protein with a compound is described. Disorders that can be treated include cancer, such as hematological cancer, pancreatic cancer, MYH associated polyposis, colorectal cancer, or lung cancer.
• US4159273A
  申请人：——

  公开号：US4159273A

  公开（公告）日：1979-06-26